Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Price Reduction Rates for 4 Major Generics Manufacturers at 8.9% to 12.2%: Jiho Survey
March 7, 2012
- Takeda US Subsidiary Millennium Begins International PIII Trial on Alisertib
March 7, 2012
- Long-Listed Drugs Account for Over 60% of Eisai’s Sales: Jiho Survey
March 7, 2012
- Worldwide Sales by Biopharmaceutical Contract Manufacturers Down Slightly in 2010 at US$3.4 Billion: Seed Planning
March 7, 2012
- Eisai to See 11%+, Lilly Japan 8-9% Average Price Reduction in FY2012 NHI Price Revision: Jiho Survey
March 6, 2012
- Nomura Securities Report Says Takeda’s TAK-875 Hoped to Become Blockbuster
March 6, 2012
- Pfizer to Outsource Clinical Trials in Japan to 2 CROs from April
March 6, 2012
- Share of Aricept Generic to Increase by Some 20% in Future: Eisai Senior Vice President Naoe
March 5, 2012
- Daiichi Sankyo, GSK Agree to Set Up Joint Venture in Vaccine Business
March 5, 2012
- Novartis Most Admired Pharmaceutical Company in IAL Survey; Will “MR quality” Be Its Achilles’ Heel?
March 5, 2012
- ReproCELL to Change Model of Drug Discovery by Launching World’s 1st iPS Cell-derived Hepatocytes
March 5, 2012
- Sanofi-aventis Nichi-Iko Withholds NHI Price Listing of Authorized Allegra Generic in June
March 2, 2012
- Eisai President Naito Approves of Government Measures, Saying Japan’s Positioning “Improving Greatly”
March 2, 2012
- Pfizer Files Lawsuit Against Sandoz for Generic Lipitor, Sandoz to Contest Action
March 2, 2012
- Carna Biosciences Aiming to Out-License First Products to Megapharma in 2012 “if Possible”
March 2, 2012
- Medipal Group to Determine Profitability with Each Customer: Next President Shuichi Watanabe
March 2, 2012
- SBI to Enter Pharmaceutical Business Through Subsidiary, Considering Domestic Plant
March 1, 2012
- Takeda Initiates PIII Clinical Trials of Leuplin 6-Month Depot Formulation in Japan
March 1, 2012
- Takeda to Issue Straight Bonds for the First Time in 25 Years to Cover Nycomed Acquisition
March 1, 2012
- Takeda to Operate Global Vaccine Business, Aiming to Join Top 5 in 10 Years
March 1, 2012
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…